Phospho‐specific plasma p‐tau181 assay detects clinical as well as asymptomatic Alzheimer's disease
Open Access
- 3 May 2022
- journal article
- research article
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 9 (5) , 734-746
Abstract
Objective: Plasma phosphorylated‐tau‐181 (p‐tau181) reliably detects clinical Alzheimer's disease (AD) as well as asymptomatic amyloid‐β (Aβ) pathology, but is consistently quantified with assays using antibody AT270, which cross‐reacts with p‐tau175. This study investigates two novel phospho‐specific assays for plasma p‐tau181 and p‐tau231 in clinical and asymptomatic AD.Methods: Plasma p‐tau species were quantified with Simoa in 44 AD patients, 40 spouse controls and an independent cohort of 151 cognitively unimpaired (CU) elderly who underwent Aβ‐PET. Simoa plasma Aβ42 measurements were available in a CU subset (N = 69). Receiver operating characteristics and Aβ‐PET associations were used to evaluate biomarker validity.Results: The novel plasma p‐tau181 and p‐tau231 assays did not show cross‐reactivity. Plasma p‐tau181 accurately detected clinical AD (area under the curve (AUC) = 0.98, 95% CI 0.95–1.00) as well as asymptomatic Aβ pathology (AUC = 0.84, 95% CI 0.76–0.92), while plasma p‐tau231 did not (AUC = 0.74, 95% CI 0.63–0.85 and 0.61, 95% CI 0.52–0.71, respectively). Plasma p‐tau181, but not p‐tau231, detected asymptomatic Aβ pathology more accurately than age, sex and APOE combined (AUC = 0.64). In asymptomatic elderly, correlations between plasma p‐tau181 and Aβ pathology were observed throughout the cerebral cortex (ρ = 0.40, p < 0.0001), with focal associations within AD‐vulnerable regions, particularly the precuneus. The plasma Aβ42/p‐tau181 ratio did not reflect asymptomatic Aβ pathology better than p‐tau181 alone.Interpretation: The novel plasma p‐tau181 assay is an accurate tool to detect clinical as well as asymptomatic AD and provides a phospho‐specific alternative to currently employed immunoassays.Keywords
Funding Information
- Flanders Innovation and Entrepreneurship (VLAIO ICON grant HBC.2019.2523, 135043)
- Fonds Wetenschappelijk Onderzoek (11M0522N, 12Y1620N, 18B2622N)
- Internationale Stichting Alzheimer Onderzoek (13007, 20170032)
This publication has 48 references indexed in Scilit:
- Amyloid imaging in cognitively normal older adults: comparison between 18F-flutemetamol and 11C-Pittsburgh compound BEuropean Journal of Nuclear Medicine and Molecular Imaging, 2015
- The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PETAlzheimer's & Dementia, 2014
- Preclinical AD predicts decline in memory and executive functions in subjective complaintsNeurology, 2013
- pROC: an open-source package for R and S+ to analyze and compare ROC curvesBMC Bioinformatics, 2011
- Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptideNature Reviews Molecular Cell Biology, 2007
- [ 11 C]PIB in a nondemented populationNeurology, 2006
- An Alternative to Cohen's Standardized Mean Difference Effect Size: A Robust Parameter and Confidence Interval in the Two Independent Groups Case.Psychological Methods, 2005
- Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardizationNeuroscience Letters, 2000
- Combining Spatial Extent and Peak Intensity to Test for Activations in Functional ImagingNeuroImage, 1997
- Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric ApproachBiometrics, 1988